Concepts (220)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anastomotic Leak | 14 | 2023 | 96 | 3.600 |
Why?
|
| Colorectal Surgery | 3 | 2023 | 22 | 2.430 |
Why?
|
| Proctocolectomy, Restorative | 6 | 2022 | 87 | 2.110 |
Why?
|
| Enterococcus faecalis | 7 | 2022 | 46 | 1.980 |
Why?
|
| Colorectal Neoplasms | 7 | 2023 | 938 | 1.890 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2022 | 71 | 1.580 |
Why?
|
| Digestive System Surgical Procedures | 4 | 2022 | 120 | 1.280 |
Why?
|
| Rectal Neoplasms | 3 | 2021 | 116 | 1.060 |
Why?
|
| Microbiota | 7 | 2023 | 378 | 1.050 |
Why?
|
| Colitis, Ulcerative | 7 | 2022 | 711 | 1.040 |
Why?
|
| Colectomy | 3 | 2020 | 167 | 1.020 |
Why?
|
| Surgeons | 4 | 2022 | 238 | 1.010 |
Why?
|
| Colon | 9 | 2022 | 496 | 0.990 |
Why?
|
| Elective Surgical Procedures | 3 | 2020 | 116 | 0.990 |
Why?
|
| Gastrointestinal Microbiome | 6 | 2021 | 453 | 0.970 |
Why?
|
| Anastomosis, Surgical | 10 | 2023 | 267 | 0.910 |
Why?
|
| Surgical Wound Infection | 2 | 2022 | 183 | 0.900 |
Why?
|
| Pouchitis | 2 | 2021 | 44 | 0.890 |
Why?
|
| Postoperative Complications | 8 | 2022 | 2205 | 0.850 |
Why?
|
| Laxatives | 1 | 2021 | 13 | 0.810 |
Why?
|
| Anti-Bacterial Agents | 5 | 2022 | 745 | 0.790 |
Why?
|
| Ileus | 1 | 2020 | 9 | 0.750 |
Why?
|
| Colonic Pouches | 4 | 2022 | 67 | 0.750 |
Why?
|
| Vital Signs | 1 | 2020 | 38 | 0.740 |
Why?
|
| Intestines | 6 | 2020 | 411 | 0.740 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 93 | 0.680 |
Why?
|
| Colonic Diseases | 1 | 2019 | 65 | 0.680 |
Why?
|
| Disease-Free Survival | 1 | 2021 | 1204 | 0.660 |
Why?
|
| Colonic Neoplasms | 1 | 2022 | 556 | 0.610 |
Why?
|
| Surgical Procedures, Operative | 1 | 2019 | 182 | 0.600 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 339 | 0.590 |
Why?
|
| Betacoronavirus | 1 | 2020 | 258 | 0.590 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2020 | 683 | 0.590 |
Why?
|
| Collagen | 3 | 2021 | 269 | 0.550 |
Why?
|
| Rectum | 3 | 2022 | 146 | 0.530 |
Why?
|
| Quality Improvement | 1 | 2019 | 428 | 0.530 |
Why?
|
| Risk Assessment | 3 | 2019 | 2261 | 0.530 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2015 | 78 | 0.510 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 316 | 0.510 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 301 | 0.510 |
Why?
|
| Humans | 39 | 2023 | 86526 | 0.490 |
Why?
|
| Inflammatory Bowel Diseases | 4 | 2021 | 549 | 0.480 |
Why?
|
| Retrospective Studies | 13 | 2022 | 8464 | 0.460 |
Why?
|
| Laparoscopy | 1 | 2020 | 754 | 0.460 |
Why?
|
| RNA, Ribosomal, 16S | 5 | 2023 | 241 | 0.440 |
Why?
|
| Intestinal Mucosa | 3 | 2018 | 797 | 0.420 |
Why?
|
| Diet, Western | 2 | 2023 | 37 | 0.410 |
Why?
|
| Plasminogen | 2 | 2021 | 41 | 0.380 |
Why?
|
| Risk Factors | 6 | 2022 | 5413 | 0.370 |
Why?
|
| Crohn Disease | 4 | 2022 | 730 | 0.310 |
Why?
|
| Dysbiosis | 2 | 2020 | 70 | 0.310 |
Why?
|
| Bacteria | 4 | 2023 | 446 | 0.290 |
Why?
|
| Dinucleotide Repeats | 1 | 2006 | 13 | 0.290 |
Why?
|
| Mice | 7 | 2023 | 11339 | 0.280 |
Why?
|
| Viral Envelope Proteins | 1 | 2006 | 94 | 0.270 |
Why?
|
| Mice, Inbred BALB C | 3 | 2023 | 1047 | 0.270 |
Why?
|
| Oligonucleotides | 1 | 2006 | 92 | 0.270 |
Why?
|
| Animals | 14 | 2023 | 26567 | 0.270 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1307 | 0.270 |
Why?
|
| Simplexvirus | 1 | 2006 | 151 | 0.260 |
Why?
|
| Collagenases | 2 | 2022 | 39 | 0.260 |
Why?
|
| Urokinase-Type Plasminogen Activator | 2 | 2022 | 47 | 0.260 |
Why?
|
| Male | 13 | 2023 | 40944 | 0.250 |
Why?
|
| Pseudomonas aeruginosa | 3 | 2021 | 193 | 0.250 |
Why?
|
| Tranexamic Acid | 2 | 2021 | 25 | 0.250 |
Why?
|
| Phenotype | 5 | 2022 | 2377 | 0.230 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 417 | 0.230 |
Why?
|
| Incidence | 3 | 2019 | 1576 | 0.230 |
Why?
|
| Hypoalbuminemia | 1 | 2022 | 9 | 0.220 |
Why?
|
| Anus Diseases | 1 | 2022 | 14 | 0.220 |
Why?
|
| Rectal Fistula | 1 | 2022 | 18 | 0.220 |
Why?
|
| Malnutrition | 1 | 2022 | 34 | 0.220 |
Why?
|
| Pressure Ulcer | 1 | 2022 | 42 | 0.210 |
Why?
|
| Antiviral Agents | 1 | 2006 | 509 | 0.210 |
Why?
|
| Illinois | 2 | 2021 | 462 | 0.210 |
Why?
|
| Matched-Pair Analysis | 1 | 2021 | 43 | 0.210 |
Why?
|
| Female | 11 | 2023 | 44489 | 0.200 |
Why?
|
| Disease Models, Animal | 3 | 2023 | 2232 | 0.200 |
Why?
|
| Adult | 8 | 2022 | 25627 | 0.200 |
Why?
|
| Middle Aged | 7 | 2022 | 25013 | 0.190 |
Why?
|
| Mouth Neoplasms | 1 | 2023 | 194 | 0.190 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2020 | 19 | 0.190 |
Why?
|
| Surgical Stomas | 1 | 2020 | 22 | 0.190 |
Why?
|
| Survival Analysis | 3 | 2020 | 1537 | 0.180 |
Why?
|
| Collagen Type IV | 1 | 2019 | 24 | 0.180 |
Why?
|
| Vitamin D Deficiency | 1 | 2021 | 103 | 0.180 |
Why?
|
| Fibrinolysis | 1 | 2019 | 35 | 0.180 |
Why?
|
| Preoperative Period | 1 | 2019 | 91 | 0.180 |
Why?
|
| Collagen Type I | 1 | 2019 | 62 | 0.180 |
Why?
|
| Drug Substitution | 1 | 2019 | 25 | 0.170 |
Why?
|
| Wound Healing | 2 | 2019 | 344 | 0.170 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2019 | 47 | 0.170 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 317 | 0.170 |
Why?
|
| Propensity Score | 1 | 2019 | 136 | 0.170 |
Why?
|
| Registries | 2 | 2021 | 702 | 0.170 |
Why?
|
| Preoperative Care | 1 | 2021 | 394 | 0.170 |
Why?
|
| Case-Control Studies | 2 | 2020 | 1803 | 0.160 |
Why?
|
| Caenorhabditis elegans | 3 | 2015 | 223 | 0.160 |
Why?
|
| Colitis | 1 | 2021 | 239 | 0.160 |
Why?
|
| Gastrointestinal Agents | 1 | 2019 | 161 | 0.150 |
Why?
|
| Cohort Studies | 2 | 2021 | 2765 | 0.150 |
Why?
|
| Biological Products | 1 | 2019 | 143 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2020 | 839 | 0.150 |
Why?
|
| Aged | 5 | 2021 | 18398 | 0.150 |
Why?
|
| Rats, Wistar | 2 | 2015 | 297 | 0.150 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 1671 | 0.150 |
Why?
|
| Rats | 4 | 2020 | 3990 | 0.150 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 423 | 0.150 |
Why?
|
| Patient Safety | 1 | 2019 | 212 | 0.150 |
Why?
|
| Host-Pathogen Interactions | 2 | 2019 | 231 | 0.140 |
Why?
|
| Prevalence | 1 | 2020 | 1239 | 0.140 |
Why?
|
| Gastrointestinal Motility | 1 | 2016 | 25 | 0.140 |
Why?
|
| Reoperation | 1 | 2018 | 597 | 0.140 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2023 | 1075 | 0.140 |
Why?
|
| Mutation | 3 | 2013 | 3960 | 0.140 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2016 | 88 | 0.130 |
Why?
|
| Interleukin-10 | 1 | 2016 | 149 | 0.130 |
Why?
|
| Household Articles | 1 | 2014 | 15 | 0.130 |
Why?
|
| Hospitals | 1 | 2017 | 293 | 0.120 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 1168 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 739 | 0.120 |
Why?
|
| United States | 3 | 2022 | 6662 | 0.120 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 3636 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 930 | 0.120 |
Why?
|
| Ischemia | 1 | 2015 | 243 | 0.110 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 1014 | 0.110 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 2705 | 0.110 |
Why?
|
| Family | 1 | 2014 | 311 | 0.110 |
Why?
|
| Adolescent | 3 | 2021 | 8976 | 0.110 |
Why?
|
| Suture Techniques | 1 | 2013 | 135 | 0.110 |
Why?
|
| Young Adult | 2 | 2021 | 5971 | 0.110 |
Why?
|
| Macrophages | 1 | 2015 | 554 | 0.100 |
Why?
|
| Prospective Studies | 1 | 2020 | 4208 | 0.100 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 6501 | 0.100 |
Why?
|
| Cell Line | 1 | 2015 | 2468 | 0.090 |
Why?
|
| Quality of Life | 1 | 2018 | 1583 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2020 | 7981 | 0.090 |
Why?
|
| Carcinogenesis | 2 | 2023 | 195 | 0.090 |
Why?
|
| Virulence | 2 | 2020 | 271 | 0.090 |
Why?
|
| Endoscopy | 2 | 2022 | 332 | 0.080 |
Why?
|
| Rib Fractures | 1 | 2008 | 8 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 3092 | 0.080 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2008 | 92 | 0.080 |
Why?
|
| Inflammation | 2 | 2023 | 919 | 0.070 |
Why?
|
| Thymine | 1 | 2006 | 17 | 0.070 |
Why?
|
| Respiratory Insufficiency | 1 | 2008 | 150 | 0.070 |
Why?
|
| Drug Resistance, Viral | 1 | 2006 | 51 | 0.070 |
Why?
|
| Vero Cells | 1 | 2006 | 100 | 0.070 |
Why?
|
| Thionucleotides | 1 | 2006 | 56 | 0.070 |
Why?
|
| Guanine | 1 | 2006 | 208 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 2354 | 0.060 |
Why?
|
| Colostomy | 1 | 2022 | 13 | 0.060 |
Why?
|
| Rectovaginal Fistula | 1 | 2022 | 7 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 133 | 0.050 |
Why?
|
| Abscess | 1 | 2022 | 91 | 0.050 |
Why?
|
| Enema | 1 | 2021 | 37 | 0.050 |
Why?
|
| Therapeutic Irrigation | 1 | 2021 | 60 | 0.050 |
Why?
|
| Microscopy, Confocal | 1 | 2021 | 268 | 0.050 |
Why?
|
| Ostomy | 1 | 2020 | 15 | 0.050 |
Why?
|
| Postoperative Period | 1 | 2021 | 303 | 0.050 |
Why?
|
| Organic Chemicals | 1 | 2019 | 33 | 0.040 |
Why?
|
| Infliximab | 1 | 2020 | 151 | 0.040 |
Why?
|
| Antifibrinolytic Agents | 1 | 2019 | 30 | 0.040 |
Why?
|
| Genome, Bacterial | 1 | 2020 | 139 | 0.040 |
Why?
|
| Proteolysis | 1 | 2019 | 100 | 0.040 |
Why?
|
| Chemoradiotherapy | 1 | 2021 | 301 | 0.040 |
Why?
|
| Pseudomonas Infections | 1 | 2019 | 95 | 0.040 |
Why?
|
| Telemedicine | 1 | 2021 | 169 | 0.040 |
Why?
|
| Long Term Adverse Effects | 1 | 2018 | 6 | 0.040 |
Why?
|
| Vitamin D | 1 | 2021 | 261 | 0.040 |
Why?
|
| Recurrence | 1 | 2021 | 1139 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 1685 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 2598 | 0.040 |
Why?
|
| Propionibacterium | 1 | 2017 | 6 | 0.040 |
Why?
|
| Staphylococcus | 1 | 2017 | 24 | 0.040 |
Why?
|
| Remission Induction | 1 | 2019 | 722 | 0.040 |
Why?
|
| Colonoscopy | 1 | 2019 | 264 | 0.040 |
Why?
|
| Time Factors | 1 | 2006 | 5209 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 2020 | 1074 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 860 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2018 | 272 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 1937 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2017 | 361 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 1 | 2023 | 1051 | 0.030 |
Why?
|
| Beds | 1 | 2014 | 5 | 0.030 |
Why?
|
| Floors and Floorcoverings | 1 | 2014 | 7 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 977 | 0.030 |
Why?
|
| Pets | 1 | 2014 | 8 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 1716 | 0.030 |
Why?
|
| Foot | 1 | 2014 | 50 | 0.030 |
Why?
|
| Obesity | 1 | 2021 | 963 | 0.030 |
Why?
|
| Patient Selection | 1 | 2018 | 685 | 0.030 |
Why?
|
| Surface Properties | 1 | 2014 | 130 | 0.030 |
Why?
|
| Nose | 1 | 2014 | 94 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2020 | 863 | 0.030 |
Why?
|
| Quorum Sensing | 1 | 2013 | 26 | 0.030 |
Why?
|
| Metagenome | 1 | 2014 | 102 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2013 | 77 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 1800 | 0.030 |
Why?
|
| Hand | 1 | 2014 | 130 | 0.030 |
Why?
|
| Mutagenesis, Insertional | 1 | 2013 | 111 | 0.030 |
Why?
|
| Radiation | 1 | 2012 | 15 | 0.030 |
Why?
|
| Protective Agents | 1 | 2012 | 33 | 0.030 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2012 | 70 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 3673 | 0.030 |
Why?
|
| Phosphates | 1 | 2012 | 160 | 0.030 |
Why?
|
| Tight Junctions | 1 | 2012 | 149 | 0.020 |
Why?
|
| Child | 1 | 2022 | 6921 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2012 | 363 | 0.020 |
Why?
|
| Base Sequence | 1 | 2012 | 2330 | 0.020 |
Why?
|
| Multiple Trauma | 1 | 2008 | 34 | 0.020 |
Why?
|
| Thoracic Injuries | 1 | 2008 | 32 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2008 | 173 | 0.020 |
Why?
|
| Age Distribution | 1 | 2008 | 204 | 0.020 |
Why?
|
| Injury Severity Score | 1 | 2008 | 111 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 3030 | 0.020 |
Why?
|
| Acute Disease | 1 | 2008 | 826 | 0.020 |
Why?
|
| Apoptosis | 1 | 2012 | 1683 | 0.020 |
Why?
|
| Logistic Models | 1 | 2008 | 1185 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 1988 | 0.010 |
Why?
|